<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11380322
   </pmid>
   <datecreated>
    <year>
     2001
    </year>
    <month>
     05
    </month>
    <day>
     30
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     12
    </month>
    <day>
     04
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0269-2813
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       15
      </volume>
      <issue>
       6
      </issue>
      <pubdate>
       <year>
        2001
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      Alimentary pharmacology &amp; therapeutics
     </title>
     <isoabbreviation>
      Aliment. Pharmacol. Ther.
     </isoabbreviation>
    </journal>
    <articletitle>
     Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
    </articletitle>
    <pagination>
     <medlinepgn>
      843-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="AIM" nlmcategory="OBJECTIVE">
      To compare the efficacy and tolerability of a 3-day quadruple therapy with a standard 7-day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Patients with H. pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3). No pre- or post-treatment acid suppression was used. Follow-up endoscopy was performed at week 6.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      A total of 118 patients were recruited. Sixty patients in the LCM-7 group and 53 patients in the LCMB-3 group returned for endoscopy. Intention-to-treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM-7 and LCMB-3 groups, respectively. Per protocol and intention-to-treat ulcer healing rates were 98% and 98% in LCM-7 and 100% and 91% in LCMB-3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side-effects was found in the LCMB-3 group.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      The 3-day quadruple therapy is highly effective, better tolerated and can be considered as a first-line therapy in duodenal ulcer management.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. bcywong@hku.hk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Wong
      </lastname>
      <forename>
       B C
      </forename>
      <initials>
       BC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wang
      </lastname>
      <forename>
       W H
      </forename>
      <initials>
       WH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wong
      </lastname>
      <forename>
       W M
      </forename>
      <initials>
       WM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lau
      </lastname>
      <forename>
       G K
      </forename>
      <initials>
       GK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fung
      </lastname>
      <forename>
       F M
      </forename>
      <initials>
       FM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kung
      </lastname>
      <forename>
       N N
      </forename>
      <initials>
       NN
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chu
      </lastname>
      <forename>
       K M
      </forename>
      <initials>
       KM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lai
      </lastname>
      <forename>
       K C
      </forename>
      <initials>
       KC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hu
      </lastname>
      <forename>
       W H
      </forename>
      <initials>
       WH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hu
      </lastname>
      <forename>
       F L
      </forename>
      <initials>
       FL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Liu
      </lastname>
      <forename>
       X G
      </forename>
      <initials>
       XG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chan
      </lastname>
      <forename>
       C K
      </forename>
      <initials>
       CK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Yuen
      </lastname>
      <forename>
       M F
      </forename>
      <initials>
       MF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hui
      </lastname>
      <forename>
       W M
      </forename>
      <initials>
       WM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lam
      </lastname>
      <forename>
       S K
      </forename>
      <initials>
       SK
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     Aliment Pharmacol Ther
    </medlineta>
    <nlmuniqueid>
     8707234
    </nlmuniqueid>
    <issnlinking>
     0269-2813
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      2-Pyridinylmethylsulfinylbenzimidazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antacids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Bacterial Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Infective Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Organometallic Compounds
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      103577-45-3
     </registrynumber>
     <nameofsubstance>
      lansoprazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      443-48-1
     </registrynumber>
     <nameofsubstance>
      Metronidazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57644-54-9
     </registrynumber>
     <nameofsubstance>
      bismuth tripotassium dicitrate
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      73590-58-6
     </registrynumber>
     <nameofsubstance>
      Omeprazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      81103-11-9
     </registrynumber>
     <nameofsubstance>
      Clarithromycin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      2-Pyridinylmethylsulfinylbenzimidazoles
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antacids
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Bacterial Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Infective Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clarithromycin
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Duodenal Ulcer
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      microbiology
     </qualifiername>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Metronidazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Omeprazole
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Organometallic Compounds
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2001
     </year>
     <month>
      11
     </month>
     <day>
      1
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      1
     </month>
     <day>
      5
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2001
     </year>
     <month>
      11
     </month>
     <day>
      1
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11380322
    </articleid>
    <articleid idtype="pii">
     apt999
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

